You’ve probably heard of BPC-157. It heals rotator cuff tears in a few weeks. Chronic knee pain disappears. It also alleviates leaky gut syndrome. This compound, a peptide derived from a protein found in human stomach acid, has gone viral on Reddit and TikTok, almost reaching the point of fandom.
BPC stands for Body Protection Compound, and “157″ refers to a specific peptide sequence isolated by researchers. It originates from a protein found in gastric juice that helps protect the stomach lining from damage. Animal studies have shown that BPC-157 has the potential to stimulate tissue repair and healing.
Due to the GLP-1 shortage and FDA restrictions on drug ingredients, a multi-billion dollar “gray market” for injectable peptide drugs is rapidly expanding online. The four words printed on these bottles should serve as a warning.
A recent study examined the effects of BPC-157 on Achilles tendon healing in rats. In this study, scientists transected the Achilles tendon in rats and treated some of them with BPC-157. The results showed that, compared to an untreated control group, the treated rats experienced improved Achilles tendon healing and functional recovery.
Related report: A successful skin-lightening peptide unexpectedly spurred the development of Vyleesi, an FDA-approved drug for low libido.
Dr. Jiam, a Beverly Hills physician and owner of Med Pod LA, discussed this study on the Live + Well podcast. He said, “One study that’s often talked about is tendon-cutting in mice. When half the mice were given BPC and the other half were given other drugs… for two months, the mice that received BPC were running around.”
These results help explain why BPC-157 has attracted so much attention in the field of injury rehabilitation, but there is an important limitation: this study was not conducted in humans.
”It also promotes angiogenesis… stimulating the formation of new blood vessels,” explained Giam. “That’s why it’s often used for muscle recovery. Bodybuilders have started using it to speed up recovery after workouts.”
Rob Fried, CEO of Niagen Bioscience, discussed nicotinamide nucleoside (NR), Tru Niagen, and new injectable, intravenous, and NAD+ home forms.
”Probably the largest number of animal studies on BPC have been conducted. There are also some human studies, but they are limited,” said Giyam, referring to the evidence base for BPC. The available human data points to gastrointestinal diseases. “Some human studies have shown that oral administration of BPC, or even rectal administration to animals, can treat various types of colitis, as it is produced from gastric juice and promotes the restoration of the gastric mucosa.”
When it comes to accident compensation claims, the data from human studies hasn’t kept pace. “We need clinical trials to prove it,” Giam noted. “You can see a lot of these cases online… but are there any reliable human studies? Not yet. I mean, we’re working on it.”
Regarding the animal studies, he stated, “The results are encouraging. The mechanism of action is clear and well-founded. However, these are not rigorous human trials. Therefore, we must take this into account.” He noted that trials are ongoing, “But they still need to monitor side effects.”
Giam stated that part of the reason for this gap is that online claims are ahead of the science. “Opinion leaders on social media can be three to five, even seven years ahead of the science. They claim… that this is some kind of magical thing that can do this and that…” He explained that there is currently no evidence to support the claims of many celebrities on social media.
It’s this uncertainty that prompts Dr. Giam to caution against using peptide medications as a quick fix. He argues that patients taking peptide medications should have a clearly defined treatment plan, rather than continuous use. “We need to understand their physical condition,” he says, “and then develop a rigorous treatment plan that includes intermittent use and discontinuation, because if the dosage is too high, it suppresses the body’s signals. The body will begin to send signals of ‘enough’ and gradually adapt.”
More importantly, Jiam argued that peptide drugs shouldn’t mask the underlying cause of the problem. “Will people change their lifestyle?” he asked. “We can’t just rely on these peptide drugs.”
More and more men, even those with typically average penis size, are choosing hyaluronic acid filler injections to increase their girth. A urologist explains the reasons for this demand, the principles of the procedure, and why this phenomenon may indicate deeper health issues in men.
He compared the situation to repeatedly damaging a car, expecting each repair to solve the underlying problem. “I tell everyone… if you’re constantly hitting the curb, we can fix your wheel, but what can you do?” he said. “You need to change your driving habits. What exactly is the problem?”
For Giam, this means looking beyond a single intervention and considering a broader range of factors that can impact a patient’s health. “You have to look at the big picture… you can’t cook with just one ingredient. You have to consider everything around you.”
The Los Angeles Times Studio shares the secrets to longevity, health tips, and expert advice to help you plan your week.
By continuing to use our service, you agree to our Terms of Service, which include the right to arbitration and waive the right to class action. You agree that we and our third-party providers may collect and use your information, including through cookies, pixels, and similar technologies, for the purposes described in our Privacy Policy, such as personalizing your experience and advertising.
Sarah Kitnick is a senior content strategist at Los Angeles Times Studios, responsible for content strategy and production for Live + Well and Hot Property.
Post time: Oct-12-2026